PDF(Pubmed)
Abstract：
BACKGROUND: Subtype diagnosis of primary aldosteronism (PA) is used to determine treatment, and the potential utility of 68Ga-pentixafor PET/CT for investigation of PA has long been recognized. The study aimed to evaluate the clinical value of 68Ga-pentixafor PET/CT in the diagnosis and prognosis of patients with bilateral lesions identified by CT.
METHODS: In total, 25 patients with PA and bilateral lesions on CT were retrospectively evaluated. All patients underwent 68Ga-Pentixafor PET/CT and adrenal vein sampling. The analysis focused on establishing the relationship between bilateral adrenal lesions SUVmax and the ratio of bilateral adrenal lesions SUVmax (CON) and clinical diagnosis, treatment outcomes, and KCNJ5 gene status.
RESULTS: The concordance rate between 68Ga-Pentixafor PET/CT and adrenal venous sampling was 65.2% (15/23). The lateralization results of 68Ga-pentixafor PET/CT supported the clinical decisions of 20 patients with PA, 90% of whom showed effectiveness in treatment. The SUVmax on the dominant side of the surgically treated patients was higher than that of patients treated with drugs. The SUVmax of the KCNJ5 mutant group was higher than that of the KCNJ5 wild group, and 68Ga-Pentixafor uptake was correlated with KCNJ5 gene status.
CONCLUSIONS: 68Ga-Pentixafor PET/CT proves beneficial for patients with PA with bilateral lesions on CT. The treatment is generally effective based on the results of PET lateralization. Simultaneously, a certain relationship exists between 68Ga-Pentixafor PET/CT and KCNJ5 gene status, warranting further analysis.
METHODS: In total, 25 patients with PA and bilateral lesions on CT were retrospectively evaluated. All patients underwent 68Ga-Pentixafor PET/CT and adrenal vein sampling. The analysis focused on establishing the relationship between bilateral adrenal lesions SUVmax and the ratio of bilateral adrenal lesions SUVmax (CON) and clinical diagnosis, treatment outcomes, and KCNJ5 gene status.
RESULTS: The concordance rate between 68Ga-Pentixafor PET/CT and adrenal venous sampling was 65.2% (15/23). The lateralization results of 68Ga-pentixafor PET/CT supported the clinical decisions of 20 patients with PA, 90% of whom showed effectiveness in treatment. The SUVmax on the dominant side of the surgically treated patients was higher than that of patients treated with drugs. The SUVmax of the KCNJ5 mutant group was higher than that of the KCNJ5 wild group, and 68Ga-Pentixafor uptake was correlated with KCNJ5 gene status.
CONCLUSIONS: 68Ga-Pentixafor PET/CT proves beneficial for patients with PA with bilateral lesions on CT. The treatment is generally effective based on the results of PET lateralization. Simultaneously, a certain relationship exists between 68Ga-Pentixafor PET/CT and KCNJ5 gene status, warranting further analysis.
摘要：
背景：原发性醛固酮增多症（PA）的亚型诊断用于确定治疗方法，68Ga-pentixa用于PET/CT研究PA的潜在用途早已得到认可。本研究旨在评估68Ga-pentixaforPET/CT在CT诊断双侧病变患者中的临床价值。
方法：总共，对25例PA和双侧病变的CT进行了回顾性评估。所有患者均接受68Ga-PentixaPET/CT和肾上腺静脉采样。分析重点是建立双侧肾上腺病变SUVmax与双侧肾上腺病变SUVmax比值(CON)与临床诊断的关系,治疗结果，和KCNJ5基因状态。
结果：68Ga-PentixaPET/CT与肾上腺静脉采样的符合率为65.2％（15/23）。68Ga-pentixaforPET/CT的侧化结果支持了20例PA患者的临床决策，其中90％在治疗中显示出有效性。手术治疗的患者的优势侧的SUVmax高于用药物治疗的患者。KCNJ5突变组的SUVmax高于KCNJ5野生组，68Ga-Pentixafor摄取与KCNJ5基因状态相关。
结论：68Ga-PentixaforPET/CT证明对CT双侧病变的PA患者有益。基于PET侧向化的结果,治疗通常是有效的。同时,68Ga-PentixaforPET/CT与KCNJ5基因状态存在一定的关系,值得进一步分析。
方法：总共，对25例PA和双侧病变的CT进行了回顾性评估。所有患者均接受68Ga-PentixaPET/CT和肾上腺静脉采样。分析重点是建立双侧肾上腺病变SUVmax与双侧肾上腺病变SUVmax比值(CON)与临床诊断的关系,治疗结果，和KCNJ5基因状态。
结果：68Ga-PentixaPET/CT与肾上腺静脉采样的符合率为65.2％（15/23）。68Ga-pentixaforPET/CT的侧化结果支持了20例PA患者的临床决策，其中90％在治疗中显示出有效性。手术治疗的患者的优势侧的SUVmax高于用药物治疗的患者。KCNJ5突变组的SUVmax高于KCNJ5野生组，68Ga-Pentixafor摄取与KCNJ5基因状态相关。
结论：68Ga-PentixaforPET/CT证明对CT双侧病变的PA患者有益。基于PET侧向化的结果,治疗通常是有效的。同时,68Ga-PentixaforPET/CT与KCNJ5基因状态存在一定的关系,值得进一步分析。
